Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-10-26 | Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since September 2021, Ms. Harper has been the Chief Business Officer of Synlogic, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines using Synlogic’s proprietary drug discovery and development platform. |
| 2022-08-05 | Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since September 2021, Ms. Harper has been the Chief Business Officer of Synlogic, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotic™ using Synlogic’s proprietary drug discovery and development platform. |
| 2023-07-12 | Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies. She has held various executive roles in biotech and pharmaceutical companies. The Board believes her significant pharmaceutical industry experience qualifies her as a director. |
| 2024-04-10 | Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies. She has an MBA from the Wharton School and serves on the board of a privately held oncology AI pathology company, but no direct software programming experience is indicated. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-19